APPlexus Hot Topics 2024

Stream on-demand webcasts and follow along with downloadable slides from APPlexus Hot Topics 2024, designed and tailored specifically for advanced practice providers, to learn about the latest updates in management of biliary tract cancer, bladder cancer, chronic lymphocytic leukemia, mantle cell lymphoma, and myeloma.

Share

Program Content

Activities

Targeted Therapies for BTC
Advances in Targeted Therapeutics for Biliary Tract Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 14, 2024

Expires: May 13, 2025

APPlexus 2024 Biliary Tract Cancer
APPlexus Hot Topics 2024: Advances in Targeted Therapeutics for Biliary Tract Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 04, 2025

Activities

Immunotherapy in MM
Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 17, 2024

Expires: May 16, 2025

Activities

bsAbs in Hem Malignancies
Redefining Precision Therapeutics in Hematologic Malignancies: Bispecific Antibodies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 17, 2024

Expires: May 17, 2025

2024 APPlexus Bispecific Antibodies Heme
Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: December 30, 2024

Activities

APPlexus: Bladder Cancer
APPlexus Hot Topics 2024: Next-Generation Care for Patients With Bladder Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2024

Expires: May 12, 2025

2024 APPlexus Bladder Cancer
Next-Generation Care for Patients With Bladder Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: May 15, 2025

Activities

Noncovalent BTKi in CLL and MCL
Clinical Updates on Noncovalent BTK Inhibitors in CLL and MCL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 14, 2024

Expires: May 13, 2025

2024 APPlexus CLL and MCL
APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2024

Expires: June 03, 2025

Faculty

cover img faculity

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider Supervisor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

cover img faculity

Caroline Kuhlman, MSN, APRN-BC

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Sandra E. Kurtin, PhD, ANP-BC, FAPO

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona
Tucson, Arizona

cover img faculity

Colleen H. Tetzlaff, MHS, PA-C

Advanced Practice Provider
Physician Assistant
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Provided by

ProCE Banner
ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supporters

Advances in Targeted Therapeutics for Biliary Tract Cancer
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Supported by an educational grant from Sanofi Genzyme.

Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies
Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Next-Generation Care for Patients With Bladder Cancer
Supported by an educational grant from Merck Sharp & Dohme LLC.

Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
Supported by an educational grant from Merck Sharp & Dohme LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme, LLC

Sanofi Genzyme

Partners

Clinical Care Options, LLC

ProCE Banner

Partners for Advancing Clinical Education (PACE)

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner